转移性中肠神经内分泌肿瘤患者18F-FDOPA PET/CT高肿瘤摄取提示预后不良:来自Groupe d'étude des Tumeurs Endocrines与ENDOCAN-RENATEN网络的研究
该研究在测试队列(n=166)和外部验证队列(n=86)中纳入2010至2021年5个专家中心连续收治的转移性中肠神经内分泌肿瘤患者,测量18F-FDOPA PET/CT肿瘤与肝脏本底的最大摄取(SUVmax和SUVpeak)。测试队列中SUVpeak肿瘤/肝脏比值>4.2者5年总生存率74.1%±4.5%,≤4.2者为95%±3.4%(P=0.01);多变量分析显示该比值>4.2与更短总生存独立相关(HR 2.30,95%CI 1.02-5.22,P=0.046)。验证队列相应5年总生存率分别为57.8%±12.5%与100%(P=0.075)。结论认为18F-FDOPA PET/CT肿瘤摄取是转移性中肠NET患者的独立预后因素。
要点
- 测试队列中SUVpeak肿瘤/肝脏比值>4.2者5年OS为74.1%±4.5%,≤4.2者为95%±3.4%(P=0.01)。
- 多变量分析中SUVpeak肿瘤/肝脏比值>4.2与更短OS独立相关(HR 2.30,95%CI 1.02-5.22,P=0.046)。
- 验证队列中比值≤4.2者5年OS为100%,>4.2者为57.8%±12.5%(P=0.075)。
核心结论
- 18F-FDOPA PET/CT肿瘤摄取是转移性中肠神经内分泌肿瘤患者的独立预后因素。
研究设计与样本
- 研究纳入测试队列(n=166)和外部验证队列(n=86),均为2010至2021年5个专家中心连续收治的转移性中肠NET患者。
- 测量每例18F-FDOPA PET/CT肿瘤与肝脏本底的SUVmax和SUVpeak,从PET/CT时点计算总生存。
- 采用Kaplan-Meier和多变量Cox比例风险分析在测试队列评估预后因素,并在验证队列重复验证。
主要发现
- 测试队列中位随访60.3个月,SUVpeak肿瘤/肝脏比值>4.2者5年OS为74.1%±4.5%,≤4.2者为95%±3.4%(P=0.01)。
- 多变量分析调整年龄、分级、既往治疗线数、转移部位数和类癌综合征后,SUVpeak肿瘤/肝脏比值>4.2仍与更短OS相关(HR 2.30,95%CI 1.02-5.22,P=0.046)。
- 验证队列中SUVpeak肿瘤/肝脏比值≤4.2者5年OS为100%,>4.2者为57.8%±12.5%(P=0.075)。
- 随时间推移SUVpeak肿瘤/肝脏比值升高倾向于具有不良预后影响。
关键数值与推荐
- SUVpeak肿瘤/肝脏比值>4.2为测试队列中与更短OS相关的阈值(P=0.01)。
- 多变量分析中比值>4.2的HR为2.30(95%CI 1.02-5.22,P=0.046)。
- 验证队列中比值≤4.2与>4.2的5年OS分别为100%与57.8%±12.5%(P=0.075)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 验证队列中比值≤4.2与>4.2的5年OS差异P=0.075,未达统计学显著。
- 随时间推移SUVpeak肿瘤/肝脏比值升高的不良预后影响仅为倾向性观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET/CT with 6-18F-fluoro-l-dopa (18F-FDOPA) has high diagnostic performance for midgut neuroendocrine tumors (NETs). We explored the prognostic role of 18F-FDOPA PET/CT uptake in metastatic midgut NETs. Methods: We included, in a test cohort (n = 166) and a full external validation cohort (n = 86), all consecutive patients with metastatic midgut NETs who underwent 18F-FDOPA PET/CT in 5 expert centers from 2010 to 2021. We measured the maximal uptake (SUVmax and SUVpeak) of the tumor and nontumor liver on each 18F-FDOPA PET/CT scan. We measured overall survival (OS) from the time of PET/CT and assessed prognostic factors using Kaplan-Meier and multivariable Cox proportional-hazards analyses in the test cohort, with replication in the validation cohort. Results: Patients had similar characteristics in both cohorts. In the test cohort, median follow-up was 60.3 mo. Patients with an SUVpeak tumor-to-liver (T/L) ratio of more than 4.2 had significantly shorter survival than those with a ratio of 4.2 or less (P = 0.01), with a 5-y OS rate of 74.1% ± 4.5% versus 95% ± 3.4%, respectively. On multivariable analysis, an SUVpeak T/L ratio of more than 4.2 remained associated with shorter OS (hazard ratio, 2.30; 95% CI, 1.02-5.22; P = 0.046) after adjustment for age, grade, number of previous lines, number of metastatic sites, and presence of carcinoid syndrome. In the validation cohort, the 5-y OS rate was 100% versus 57.8% ± 12.5% in patients with an SUVpeak T/L ratio ≤ 4.2 or > 4.2, respectively (P = 0.075). An increasing SUVpeak T/L ratio over time tended to have a pejorative prognostic impact. Conclusion: Tumor uptake on 18F-FDOPA PET/CT is an independent prognostic factor in patients with metastatic midgut NETs.
引用
- De Rycke O, Perrier M, Ouvrard É, et al. High Tumor Uptake on 18F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d'étude des Tumeurs Endocrines and ENDOCAN-RENATEN Network. J Nucl Med. 2023. PMID: 37652547. doi:10.2967/jnumed.123.265584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。